MicroRNAs (miRNAs) are small (~22 nt) noncoding single-stranded RNA molecules that 18 downregulate gene expression. Studies have shown that miRNAs control diverse aspects of heart 19 disease, including hypertrophy, remodeling, heart failure, and arrhythmia. Recently, several 20 studies have suggested that miRNAs contribute to ischemia-reperfusion injury by altering key 21 signaling elements, thus making them potential therapeutic targets. By altering the expression of 22 various key elements in cell survival and apoptosis (such as PI3K, PTEN, Bcl-2, Mcl-2, HSP60, 23 HSP70, HSP20, Pdcd4, LRRFIP1, FasL, Sirt-1, etc), miRNAs alter the response to ischemia-24 reperfusion injury. Studies using various in vivo, ex vivo and in vitro models have suggested the 25 possible involvement of miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320 in 26 ischemia-reperfusion injury and/or remodeling after myocardial infarction. Thus, miRNA-based 27 therapy could be potential therapeutic targets for the treatment of heart disease. inhibition. Studies have shown that miRNAs control diverse aspects of heart disease, including 40 hypertrophy, remodeling, heart failure, and arrhythmia (2, 11, 33, 37, 39, 45). Recently, several 41 studies have suggested that miRNAs contribute to ischemia-reperfusion injury by altering key 42 signaling elements, thus making them potential therapeutic targets. 43
various key elements in cell survival and apoptosis (such as PI3K, PTEN, Bcl-2, Mcl-2, HSP60, 23 HSP70, HSP20, Pdcd4, LRRFIP1, FasL, Sirt-1, etc), miRNAs alter the response to ischemia-24 reperfusion injury. Studies using various in vivo, ex vivo and in vitro models have suggested the 25 possible involvement of miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320 in 26 ischemia-reperfusion injury and/or remodeling after myocardial infarction. Thus, miRNA-based 27 therapy could be potential therapeutic targets for the treatment of heart disease. Inhibiting 28 miRNAs by antisense strategies or pharmacological approaches is likely to emerge as an 29 alternative and safe method for conferring short-and intermediate-term protection against 30 ischemia-reperfusion injury. 31
In the mouse heart, Roy and colleagues (31) studied the expression of 661 miRNAs in 125 response to ischemia-reperfusion injury and found that 13 miRNAs were significantly 126 upregulated on day 2 after infarction, and on day 7 postinfarction, 9 were upregulated and 6 127 downregulated. MiR-21 levels increased primarily in cardiac fibroblasts in the infarcted area but 128 not in the noninfarcted area. (31). However, they did not study changes in miR-21 levels during 129 the period of acute ischemia or early during reperfusion when most cell death occurs. Their 130 earliest time point of study was day 2, when reparative processes are beginning. Thus, their 131 experimental design is compatible with remodeling rather than acute ischemia-reperfusion 132 injury, and early induction of miR-21 in cardiomyocytes during ischemia or early reperfusion 133 cannot be excluded. 134 PTEN degrades phosphatidylinositol (3,4,5) P(3), which is produced by phosphoinositide 135 3-kinase (PI3K) and is essential for activation of the prosurvival Akt kinase pathway (16, 21) . 136
PTEN is involved in protection against ischemia-reperfusion injury (21). Inhibition of PTEN 137
limits myocardial infarction size (16). Upregulation of miR-21 is expected to inhibit PTEN and, 138 therefore, promote cell survival. Indeed, Roy and colleagues (31) have shown that miR-21 139 inhibition increases the expression of PTEN, whereas miR-21 mimic oligonucleotide suppresses 140 PTEN in cardiac fibroblasts. In addition, they showed that miR-21 controls matrix 141 metalloproteinase-2 (MMP-2) expression via a PTEN pathway. MMP-2 is involved in mediating 142 ischemia-reperfusion injury and in other pathological conditions including oxidative stress, heart 143 failure and inflammation (42) . 144
Cheng and colleagues (8) In contrast, Sayed and colleagues (32) reported that miR-21 levels decreases in 1-2 day 157 old rat cardiomyocytes exposed to hypoxia (by 40% within 1 hour and by 75% within 12~24 158 hours), and leads to upregulation of PTEN and Fas Ligand (FasL). They found similar results in 159 mice after 6 h of coronary artery occlusion. During short-term exposure of cells to hypoxia (~15 160 minutes), Akt phosphorylation (resulting in Akt activation) and PTEN phosphorylation (resulting 161 in PTEN deactivation) were enhanced, and miR-21 expression was upregulated. However, 162 during prolonged ischemia, Akt activity was downregulated, leading to decreased levels of miR-163 21 level with subsequent upregulation of PTEN and FasL (32) . Moreover, during prolonged 164 ischemia PTEN phosphorylation is decreased, leading to PTEN activation with subsequent 165 deactivation of Akt (32). In a transgenic mouse model overexpressing miR-21, Sayed and 166 colleagues (32) found that miR-21 overexpression suppressed ischemia-induced upregulation of 167 PTEN and FasL, with a subsequent increase in Akt phosphorylation, limiting infarct size and 168 attenuating apoptosis. Thus, miR-21 activates Akt via suppression of PTEN, whereas Akt upDong and colleagues (12) studied miRNA expression in infarcted zones, border zones, 171 and noninfarcted zones in rats exposed to permanent coronary artery occlusion. They found that 172 miR-21 was downregulated in the infarcted areas but upregulated in the border areas at 6 hours 173 after coronary artery occlusion. Furthermore, ischemic preconditioning inhibited the 174 downregulation of miR-21 in the infarcted areas. Overall, expressions of 38 miRNAs were 175 affected in the infarcted areas and 33 miRNAs in the border areas as compared with those in the 176 noninfarcted areas (12). Transfection with adenovirus expressing miR-21 reduced cell apoptosis 177 in the border and the infarcted areas, decreased myocardial infarction size, and improved left 178 ventricular remodeling 2 weeks after infarction (12). In vitro experiments, using adult rat 179 cardiomyocytes, showed that miR-21 protected against ischemia-reperfusion injury and 180 confirmed that PDCD4 was a target of miR-21 with downstream activation of AP-1 (12). 181
Interestingly, Dong and colleagues (12) found that miR-21 expression was also increased in the 182 noninfarcted areas of infarcted hearts and that ischemic preconditioning increased the levels in 183 noninfarcted areas. These findings are in accordance with the fact that preconditioning by brief 184 occlusion of one coronary artery confers protection in myocardial areas supplied by other 185 coronary arteries (28). 186 Yin and colleagues (50) reported that ischemic preconditioning upregulated miR-1, miR-187 21, and miR-24. Injection of these miRNAs into the left ventricular wall of mice reduced infarct 188 size and induced expression of endothelial nitric oxide synthase (eNOS), heat shock transcription 189 factor 1 (HSF-1) and HSP70 (50). 190
Taken together, these results suggest that miR-21 is involved in prosurvival signaling. (41) showed that collagen expression was reduced in fibroblasts overexpressing 226 miR-29 and that fibrosis was induced by inhibiting miR-29. 227
The timing of intervention is important. Early inhibition of miR-29 just before ischemia, 228 reduced infarction size, whereas longer-term inhibition of miR-29 after infarction augmented 229 fibrosis. Thus, overexpressing miR-29 may be beneficial in the remodeling phase, whereas in the 230 acute phase inhibition is beneficial. 231 miR-92a 232 miR-92a enhances vessel growth in various models. Bonauer and colleagues (4) reported that 233 miR-92a levels were increased 24 h after coronary artery occlusion in mice. Furthermore, they 234
showed that injection of antagomir-92a at 0, 2, 4, 7, and 9 days after permanent coronary artery 235 occlusion in mice improved left ventricular function, reduced myocardial infarction size 236 (measured 2 weeks after infarction), reduced apoptosis, and increased the number of new blood 237 vessels, especially in the border areas of infarction (4). Sirtuin 1 (Sirt1), a longevity gene, is a 238 putative target of miR-92a (and of miR-199a as described below) (4). Overexpressing miR-92a 239 decreased the expression of integrin subunits α5 (ITGA5) and αv, sphingosine-1-phosphate 240 receptor 1 (S1P1), mitogen-activated kinase kinase 4 (MKK4), and eNOS (4). Thus, inhibiting 241 miR-92a may potentially reduce infarct size and improve remodeling and neovascularization 242 after myocardial infarction. 243 miR-126 244 miR-126 is highly expressed in heart and lung tissue. miR-126 enhances the proangiogenic 245 actions of VEGF and FGF and promotes blood vessel formation by repressing the expression of 246
Sprouty-related protein-1 (Spred-1), an intracellular inhibitor of angiogenic signaling (43) and 247
Vascular cell adhesion molecule 1 (VCAM-1) (13). Levels of miR-126 are increased in the non-248 infarcted zone at 6 h after permanent coronary artery occlusion (12) and 24 h after 30 min 249 ischemia (36). The survival rate in miR-126 null mice following permanent coronary artery 250 ligation is significantly reduced compared to wild-type mice, due to defective angiogenesis (43). 251 miR-126 is present in apoptotic bodies and represses the function of regulator of G protein 252 (heterotrimeric guanosine triphosphate-binding protein) signaling 16, an inhibitor of G protein-253 coupled receptor (GPCR) signaling. This enabled CXCR4, a GPCR, to trigger an autoregulatory 254 feedback loop that increased the production of CXCL12. Activation of the CXCL12 chemokine 255 receptor CXCR4 counteracts apoptosis and recruit progenitor cells (51). Thus, currently, we have 256 evidence that miR-126 is involved mainly in the reparative phase after myocardial injury by 257 promoting recruitment of progenitor cells and enhancing angiogenesis. 258 miR-133 259 miR-133 is expressed in adult cardiomyocytes and skeletal muscle. In patients who died of 260 myocardial infarction, miR-133 levels are reduced in the infarcted areas of the heart (5). 261
Overexpressing miR-133 reduced apoptosis and increased viability of H9c2 cells after exposureto H 2 O 2 , whereas downregulating miR-133 expression by using an inhibitory oligonucleotide 263 promoted apoptosis in these cells and in neonatal rat ventricular cardiomyocytes (44). 264
Computational and bioinformatic studies (44) have identified caspase-9 as a potential target of 265 miR-133. miR-133 decreased the level and activity of caspase-9, whereas anti-miR-133 266 oligonucleotides abrogated this effect, suggesting that miR-133 has an antiapoptotic effect by 267 suppressing caspase-9. 268
miR-199a 269
Rane and colleagues (29) have reported that miR-199a targets hypoxia-inducible factor-1α (Hif-270 1α) and Sirt1, suggesting that miR-199a is involved in early ischemic and hypoxic 271 preconditioning. In mouse studies, they reported that mature miR-199a was undetectable in the 272 heart as early as 30 min after coronary artery occlusion, whereas its precursor accumulated over 273 time (29) . Overexpression of miR-199a inhibited hypoxia-induced expression of proapoptotic 274 proteins, such as caspase-3, caspase-6, caspase-9, caspase-12, FasL, AIF, and Bnip1, in neonatal 275 rat cardiomyocytes (29) . 276
Hif-1α, a predicted target of miR-199a, is rapidly induced by hypoxia and is involved in 277 hypoxic preconditioning. A luciferase activity test showed that miR-199a interacted with the 3'-278 UTR of Hif-1α and that inhibiting miR-199a induced the expression of Hif-1α in cardiomyocytes 279 (29). Both hypoxic preconditioning and silencing miR-199a were associated with upregulation of 280 inducible nitric oxide synthase (iNOS) and Bcl-2, whereas overexpression of miR-199a 281 prevented upregulation of iNOS during hypoxic preconditioning (29). 282
Another target of miR-199a predicted by the computational analysis is Sirt1, a class III 283 histone deacetylatase and longevity gene (29). Overexpression of miR-199a reduced Sirt1 level, 284 whereas silencing miR-199a by antisense oligonucleotide or by hypoxic preconditioningincreased Sirt1 levels (29). Interestingly, they found that Sirt1 downregulated prolyl hydroxylase 286 2, which destabilizes Hif-1α (29). Thus, downregulation of miR-199a induced protection against 287 ischemia-reperfusion injury both by decreasing suppression of translation of Hif-1α and by 288 enhancing its stability via Sirt1-induced inhibition of prolyl hydroxylase 2 (29). 289 miR-320 290 Studies (30) have shown that miR-320 is downregulated in mouse hearts after 30 min of 291 ischemia and 24 h of reperfusion (in vivo), or after 45 min of no-flow global ischemia and 2 h of 292 reperfusion (ex vivo). In vitro experiments using adult rat cardiomyocytes showed that 293 overexpression of miR-320 increased cell death and apoptosis, whereas silencing miR-320 294 reduced cell death and apoptosis. Moreover, transgenic mice with cardiac-specific 295 overexpression of miR-320 had a larger myocardial infarction size than wild type mice after 296 ischemia-reperfusion. However, inhibiting miR-320 with antagomir-320 significantly reduced 297 infarction size (30). Furthermore, miR-320 downregulated HSP20, a protein that protects the 298 heart against ischemia-reperfusion injury, indicating that HSP20 is a putative target of miR-320 299 (30). 300
Conclusion 301
Taken together, the results described above show complex and highly variable changes in 302 expression of various miRNAs during and after ischemia or ischemia-reperfusion. These changes 303 should be incorporated into the current understanding of the complex dynamic transcriptional 304 and post-transcriptional changes that occurs in numerous pro-survival and pro-apoptotic 305 mediators at various cells types in response to ischemia and ischemia/reperfusion injury. It is 306 plausible that in response to brief ischemia or short cycles of non-lethal ischemia-reperfusion 307 insults, alterations in miRNAs expression favoring survival are activated in cardiomyocytes, 308 endothelial cells and/or other types of cells. However, with prolonged ischemia leading to 309 irreversible damage, the prosurvival signals are turned off and pro-apoptotic miRNAs changes 310 occur. Later on, there are changes in miRNA levels that increase fibrosis in fibroblasts at the 311 infarcted zone, in conjunction with stimulation of hypertrophic signaling pathways known to 312 play a role in remodeling and angiogenesis at the border zone as well as the more remote 313 myocardial zones. Thus, different changes are expected to occur at different time points and in 314 different cell types located in the infarcted zone, border zone and remote myocardial regions. 315
Moreover, it is plausible that different animal strains, gender and age may affect the miRNAs 316 response to ischemia or ischemia-reperfusion injury. Furthermore, we cannot exclude that 317 different anesthetic agents may affect miRNAs expression, as they have effects on 318 preconditioning and infarct size. Indeed, the experimental data support complex and location-319 and time-dependent changes in miRNAs expression (See above and Table 1 ). Moreover, 320 ischemia-reperfusion induces alteration in the expression of several miRNAs, each one of them 321 has numerous potential targets (Table 2) . Together with alterations in the transcription and post-322 trascriptional modification of various key signaling pathways, changes in miRNA expression 323
should be see as part of a network response and do not stand alone, as it is depicted in most 324 experimental studies. 325
It is commonly believed that acute ischemia-reperfusion injury occurs within minutes of 326 reperfusion. However, apoptosis may continue for hours and days after reperfusion. It is very 327 difficult to separate changes that are related to delayed ischemia-reperfusion injury from those 328 that are related to remodeling. Some of the changes in miRNAs expression described above are 329 related to angiogenesis; and hence, should be classified as "remodeling" rather than toNevertheless, the abovementioned data suggest that specific miRNAs are important in 332 controlling ischemia-reperfusion injury and that miRNAs may be potential therapeutic targets for 333 the treatment of heart disease. Per definition, preconditioning (either by ischemia or other 334 mechanical interventions or by pharmacological agents) should be administered before the 335 ischemia-injury insult. Utilization of preconditioning in the clinical setting may occur as short or 336 medium-term pretreatment before planned ischemia (elective cardiac or non cardiac surgery, 337 percutaneous coronary intervention, etc); or alternatively, as long-term treatment to "protect the 338 heart" if prolonged ischemia occurs. As miRNAs have numerous potential effects that may affect 339 various cell types and tissues, long term administration therapies should be carefully assessed for 340 potential benefits, as well as adverse effects and safety. Postconditioning, on the other hand, 341 refers to interventions that are done during ischemia or the early phase of reperfusion to 342 minimize the reperfusion part of ischemia-reperfusion injury. In the clinical setting 343 postconditioning can be used mainly for patients presenting with ongoing ischemia (ST elevation 344 myocardial infarction). This mandates a simple route for administration of the drug and early 345 onset of action. Currently, it is unclear how fast miRNA mimic or inhibitory agents can penetrate 346 the cells and exert their transcriptional changes. If it will be possible to show that such changes 347 occur within minutes after intravenous or intracoronary administration, miRNA-based therapy 348
should be tested as a mean to limit acute ischemia-reperfusion injury ("postconditioning"). 349
Inhibiting miRNAs by antisense strategies or pharmacological approaches is likely to emerge as 350 an alternative and safe method for conferring short-and intermediate-term protection against 351 ischemia-reperfusion injury (for example, before percutaneous coronary interventions or high-352 risk surgery). miRNAs-based therapy has a potential to improve remodeling and prevents the 353 deterioration of heart function and development of heart failure post myocardial infarction. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by 484 targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. Journal of cell science 120: 3045-485 Integrin subunit α5 (ITGA5) (4) Integrin subunit αV (ITGAV) (4)
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